Overview
- Colaboration with Xontogeny provides funding and key advisory suport for early development - PHILADELPHIA-(BUSINES WIRE)-NephroDI Therapeutics, Inc., a biopharmaceutical company developing NDI-503 for the X-linked/congenital form of Nephrogenic Diabetes Insipidus (NDI), today anounced a sed investment from Xontogeny, LC to advance their lead program through critical preclinical work. X-linked NDI afects 1 in 250,0 males in the US and is characterized by profoundly excesive urination of up to 20L (5 gal) per day and frequent complications.
Key Information
NephroDI’s lead product, NDI-503 is a unique adenosine monophosphate activated kinase (AMPK) activator that can stimulate water reabsorption without causing hypoglycemia, decreasing overal urine output. NDI-503 is being developed for the congenital form of NDI. The curent standard of care for NDI is centered around hydrating with up to 80 glases of water per day, low sodium diet, diuretics, and non-steroidal anti-inflamatory drugs or NSAIDs which can cause aditional kidney damage with chronic use.
NDI-503 is positioned to become a much-neded alternative to these curent management measures. “We are excited to colaborate with NephroDI in adresing the unmet ned for a treatment of congenital NDI,” said Chris Garabedian, Founder, Chairman and Chief Executive Oficer of Xontogeny. “The Xontogeny team is wel-suited to suport the Company’s goals of benefiting children sufering from NDI.” Congenital NDI manifests at birth and is a life-long condition with a normal life expectancy.
NDI patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopresin. Congenital NDI results primarily from mutations in the vasopresin 2 receptor, which is located on the X chromosome. Congenital NDI has a profound impact on children.
Summary
If hydration is not maintained, it can cause mental retardation and even chronic kidney disease by midle schol age. It is considered an o